Multidrug resistance gene expression in acute myeloid leukemia: Major prognosis significance for in vivo drug resistance to induction treatment

Annals of Hematology

Volumn 74, Issue 2, 1997, Pages 65-71

  Hunault, M ^a   Zhou, D ^a   Delmer, A ^a   Ramond, S ^a   Viguie F ^a   Cadiou, M ^a   Perrot, J Y ^a   Levy, V ^a   Rio, B ^a   Cymbalista, F ^a   Zittoun, R ^a   Marie, J P ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Acute myelogenous leukemia; Multidrug resistance; Prognosis

Indexed keywords

CYTARABINE; INTERCALATING AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

ADULT; AGED; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; FEMALE; GENE EXPRESSION; GENES, MDR; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PHENOTYPE; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031052883     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050259     Document Type: Article

References (32)

1. Arthur D, Berger R, Colomb H, Swansbury G, Reeves B, Berghe HVD, Boomfield C, Capelle ADL, Dewald G, Garson O, Hagemeijer A, Kaneko Y, Mitelman F, Pierre R, Ruutu T, Sakurai M, Lawler S, Rowley J (1989) The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet Cytogenet 40:203-216
2. Baudard M, Marie J, Cadiou M. Viguié F, Zittoun R (1994) Acute myelogenous leukemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 86:82-91
3. Bennett J, Catovsky D, Daniel M, Flandrin G, Galton D, Gralnick H, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:620-625
4. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D (1992) Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79:473-476
5. Cevreska L, Gale R (1987) Prognostic factors in acute mylogenous leukemia. Hamatol Bluttransfus 30:376-379
6. Cole S, Bhardwaj G, Gerlach J, Mackie J, Grant C, Almquist KC, Stewart A, Kruz E, Duncan A, Deeley R (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654
7. Del Poeta G, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A, Buccisano F, Masi M, Tribalto M, Amadori S, Papa G (1996) Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 87:1997-2004
8. Ellison R, Holland J, Weil M, et al. (1968) Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 32:507-522
9. Endicott J, Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 58:137-171
10. Estey E (1995) Treatment of acute myelogenous leukemia and myelodysplastic syndromes. Semin Hematol 32:132-151
11. Fisher G, Sikic B (1995) Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 9:363-381
12. Hart S, Ganeshaguru K, Hoffbrand A, Prentice H, Metha A (1994) Expression of the multidrug resistance-associated protein (MRP) in acute leukemia. Leukemia 8:2163-2168
13. Kaplan E, Meier R (1958) Non-parametric estimation from incomplete observations. J Am Stat Asso 53:457-481
14. Keating M, Smith T, Kantarjian H (1988) Cytogenetic pattern in acute myeloid leukemia: a major reproductible determinant of outcome. Leukemia 2:403-412
15. Kuriyama K, Tomonaga M, Matsuo T, Kobayashi T, Miwa H, Shirakawa S, Tanimoto M, Adachi K, Emi N, Hiraoka A, Tominaga N, Imai K, Asou N, Tsubaki K, Takahashi I, Minami S, Yoshida M, Murakari H, Minato K, Oshima T, Furusawa S, Ohno R (1994) Poor response to intensive chemotherapy in de novo acute myeloid leukemia with trilineage myelodysplasia. Br J Haematol 86:767-773
16. Lamy T, Goasguen J, Mordelet E, Grulois I, Dauriac C, Drenou B, Chaperon J, Fauchet R, Le Prise P (1994) P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML). Leukemia 8:1879-1883
17. Leith C, Kopecky K, Chen I, Godwin J, Appelbaum F, Head D, Willman C (1995) Multidrug resistance (MDR-1) expression and function in acute myeloid leukemia (AML) in the elderly: MDR-1 and secondary AML status are independent predictors of complete remission (CR). Leukemia 9:535
18. Marie J (1996) MDR 1/P-glycoprotein in haematological neoplasms. Eur J Cancer 32A:1034-1038
19. Marie J, Zittoun R, Sikic B (1991) Multidrug resistance (MDR 1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78:586-592
20. Noonan K, Beck C, Holzmayer T (1991) Quantitative analysis of MDR-1 gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87:7160-7164
21. Pirker R, Wallner J, Geissler K, Linkesch W, Haas O, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, Ludwig H, Lechner K (1991) MDR-1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83:708-712
22. Pirker R, Wallner J, Götzl M, Gsur A, Geissler K, Havelec L, Knapp W, Haas O, Linkesch W, Lechner K (1992) MDR 1 RNA expression is an independent prognostic factor in acute myeloid leukemia. Blood 80:557-558
23. Schneider E, Cowan K, Ader H, Toomey S, Schwartz G, Karp J, Burke P, Kaufmann S (1995) Increased expression of the multidrug resistance-associated protein gene in relapsed leukemia. Blood 85:186-193
24. Stone R, Mayer R (1993) Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematol Oncol Clin North Am 7:47-64
25. te Boekhorst P, de Leeuw K, Schoester M, Wittebol S, Nooter K, Hagemeijer A, Löwenberg B, Sonneveld P (1993) Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. Blood 82:3157-3162
26. Tiirikainen M, Elonen E, Ruutu T, Jansson S, Krusius T (1993) Clinical significance of P-glycoprotein expression in acute leukaemia as analysed by immunocytochemistry. Eur J Haematol 50:279-285
27. Wood P, Burgess R, MacGregor A, Liu Yin JA (1994) P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 87:509-514
28. Zhou DC, Marie JP, Suberville AM & Zittoun R (1992) Relevance of MDR-1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 6:879-885
29. Zhou DC, Zittoun R, Marie JP (1995) Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR 1) genes in acute myeloid leukemia. Leukemia 9:1661-1666
30. Zittoun R, Jehn U, Fiere D, Haanen C Lowenberg B, Willemze R, Abels J, Bury J, Peetermans M, Hayat M, Suciu S, Solbu G, Stryckmans P (1989) Alternating v repeated postremission treatment in adult myelogenous leukemia: a randomised phase III study (AML6) of the EORTC leukemia cooperative group. Blood 73:896-906
31. Zittoun R, Mandelli F, Willemze R, Witte TD, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Strickmans P, Rotoli B, Leoni P, Peetermans M, Dardenne M, Vegna M, Petti M, Solbu G, Suciu S (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 323:217-223
32. Zöchbauer S, Gsur A, Brunner R, Kyrie P, Lechner K, Pirker R (1994) P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 8:975-977